Peripheral mechanisms for the initiation of pain following trigeminal nerve injury.
Injury to a branch of the trigeminal nerve may lead to the development of chronic pain in the affected area. The etiology of this condition is not clear, but there is strong evidence to suggest that spontaneous and mechanically induced neural discharge from the injury site plays a crucial role. In laboratory studies, we have characterized this discharge following injury to the inferior alveolar or lingual nerves and have shown a temporal association with the accumulation of neuropeptides in the damaged axons. Substance P, calcitonin gene-related peptide, and vasoactive intestinal polypeptide were all found to be capable of increasing the discharge when applied systemically, and enkephalin caused a decrease. There were also changes in the expression of specific sodium channels and nitric oxide synthase, both at the injury site and in the trigeminal ganglion. Studies on lingual nerve neuromas taken from patients undergoing nerve repair also revealed accumulation of peptides, as well as inflammatory and structural changes, but the presence of these features did not correlate directly with the reported symptoms. The application of corticosteroids to an experimental injury site decreased the mechanically induced discharge, and the anticonvulsant carbamazepine reduced the spontaneous discharge in some axons. Some of the responses that result from damage to a branch of the trigeminal nerve appear to differ from those that follow damage to other peripheral nerves. These differences will need to be taken into account when developing new therapeutic approaches for the management of injury-induced trigeminal pain.
Robinson
Peter P
PP
Department of Oral and Maxillofacial Surgery, School of Clinical Dentistry, University of Sheffield, Claremont Crescent, Sheffield S10 2TA United Kingdom. p.robinson@sheffield.ac.uk
Boissonade
Fiona M
FM
Loescher
Alison R
AR
Smith
Keith G
KG
Yates
Julian M
JM
Elcock
Claire
C
Bird
Emma V
EV
Davies
Shelley L
SL
Smith
Paula L
PL
Vora
Amit R
AR
D000200:Action Potentials; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D002220:Carbamazepine / Q000627:therapeutic use; D020209:Cranial Nerve Injuries / Q000150:complications* / Q000378:metabolism; D006801:Humans; D061222:Lingual Nerve Injuries; D009479:Neuropeptides / Q000378:metabolism; D015222:Sodium Channels / Q000378:metabolism; D014222:Triamcinolone Acetonide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D061221:Trigeminal Nerve Injuries; D014277:Trigeminal Neuralgia / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism / Q000473:pathology
D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants; D009479:Neuropeptides; D015222:Sodium Channels; D002220:Carbamazepine; D014222:Triamcinolone Acetonide; C005900:triamcinolone hexacetonide